Format

Send to

Choose Destination
Zhong Xi Yi Jie He Xue Bao. 2003 Sep;1(3):184-6.

[Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer].

[Article in Chinese]

Author information

1
Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

Abstract

OBJECTIVE:

To observe the clinical effect of cinobufacini injection in treating moderate and advanced primary liver cancer (PLC).

METHODS:

One hundred patients with moderate and advanced PLC were randomly divided into cino-treated group (50 patients) and control group (50 patients). The quality of life, tumor size, some changes of laboratory tests, and survival time were observed.

RESULTS:

The progressive rate of cino-treated group (18%) was lower than that of the control group (32%). The quality of life of the cino-treated group (80%) was better than that of the control group (72%), but without statistical significance. The survival rate of >12 months of the cino-treated group (30%) was higher than that of the control group (18%). The patients' liver function such as serum total bilirubin and ALT decreased obviously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the control group while there was no statistical significance in the cino-treated group.

CONCLUSION:

Cinobufacini injection can not only inhibit the proliferation of cancer, but also protect liver function, improve quality of life and prolong survival time.

PMID:
15339556
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center